Endothelial progenitor cells (EPCs) have an important role in repair following vascular injury. However, in patients with diabetes, EPC number and function are markedly reduced. It is unclear whether intensive glycaemic control can modify EPC properties in diabetic patients. We aimed to examine whether glycaemic control can improve EPC number and function in patients with long-standing uncontrolled type 2 diabetes.
Methods and Results
Thirty-five patients with treated type 2 diabetes and HgA1c ≥8.5% were included. Patients were tested at baseline and after 3–4 months of an intensive glycaemic control programme, with the aim of achieving HgA1c of 7%. The diabetes group was compared to 20 patients without diabetes (control). Circulating EPC levels were assessed by flow cytometry for expression of VEGFR2, CD133, and CD34. The capacity of the cells to form colony-forming units (CFUs), and their migration and viability were quantified after 1 week of culture. Patients with diabetes (mean age 61.1 ± 7 years, 28.6% women, disease duration of 19.2 ± 8 years) had a baseline HgA1c of 9.4 ± 0.8%. After the glycaemic control period, HgA1c decreased to 8 ± 0.8%. Circulating EPC levels increased significantly after the intensive control period and reached a level similar to the control group. The number of EPC CFUs also increased significantly after glycaemic control but remained lower than the control group. All EPC functional assays improved following the glycaemic control.
Conclusions
In patients with uncontrolled long-standing type 2 diabetes, intensive glycaemic control was associated with an increase in the levels of circulating EPCs, and improvement in their functional properties.
RoglicGUnwinNBennettPH. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care2005; 28: 2130–2135.
2.
UrbichCDimmelerS. Endothelial progenitor cells characterization and role in vascular biology. Circ Res2004; 95: 343–353.
3.
HristovMZerneckeALiehnEA. Regulation of endothelial progenitor cell homing after arterial injury. Thromb Haemost2007; 98: 274–277.
4.
WalterDHRittigKBahlmannFH. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation2002; 105: 3017–3024.
5.
WernerNPrillerJLaufsU. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol2002; 22: 1567–1572.
6.
PeichevMNaiyerAJPereiraD. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood2000; 95: 952–958.
7.
HristovMWeberC. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med2004; 8: 498–508.
8.
AsaharaTMasudaHTakahashiT. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res1999; 85: 221–228.
9.
GehlingUMErgünSSchumacherU. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood2000; 95: 3106–3112.
10.
VasaMFichtlschererSAicherA. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res2001; 89: E1–E7.
11.
EizawaTIkedaUMurakamiY. Decrease in circulating endothelial progenitor cells in patients with stable coronary artery disease. Heart2004; 90: 685–686.
12.
HillJMZalosGHalcoxJP. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med2003; 348: 593–600.
13.
WernerNKosiolSSchieglT. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med2005; 353: 999–1007.
14.
FadiniGPBoscaroEde KreutzenbergS. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care2010; 33: 1097–1102.
15.
FadiniGPMiorinMFaccoM. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol2005; 45: 1449–1457.
16.
FadiniGPSartoreSAlbieroM. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol2006; 26: 2140–2146.
17.
EganCGLaveryRCaporaliF. Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia2008; 51: 1296–1305.
18.
LiaoYFChenLLZengTS. Number of circulating endothelial progenitor cells as a marker of vascular endothelial function for type 2 diabetes. Vasc Med2010; 15: 279–285.
19.
TepperOMGalianoRDCaplaJM. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation2002; 106: 2781–2786.
20.
CaballeroSSenguptaNAfzalA. Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells. Diabetes2007; 56: 960–967.
21.
De FalcoEAvitabileDTottaP. Altered SDF-1-mediated differentiation of bone marrow-derived endothelial progenitor cells in diabetes mellitus. J Cell Mol Med2009; 13: 3405–3414.
22.
SorrentinoSABahlmannFHBeslerC. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation2007; 116: 163–173.
23.
YueWSLauKKSiuCW. Impact of glycemic control on circulating endothelial progenitor cells and arterial stiffness in patients with type 2 diabetes mellitus. Cardiovasc Diabetol2011; 10: 113–113.
24.
WangCHTingMKVermaS. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am Heart J2006; 152: 1051.e1–e8.
25.
MakinoHOkadaSNagumoA. Pioglitazone treatment stimulates circulating CD34-positive cells in type 2 diabetes patients. Diabetes Res Clin Pract2008; 81: 327–330.
26.
FadiniGPde KreutzenbergSVMarianoV. Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. Diabetes Obes Metab2011; 13: 718–725.
27.
ReinhardHJacobsenPKLajerM. Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes. Diabetologia2010; 53: 2129–2133.
28.
KusuyamaTOmuraTNishiyaD. Effects of treatment for diabetes mellitus on circulating vascular progenitor cells. J Pharmacol Sci2006; 102: 96–102.
29.
LevEILeshem-LevDMagerA. Circulating endothelial progenitor cell levels and function in patients who experienced late coronary stent thrombosis. Eur Heart J2010; 31: 2625–2632.
30.
VasaMFichtlschererSAdlerK. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation2001; 103: 2885–2890.
31.
ChenJZZhuJHWangXX. Effects of homocysteine on number and activity of endothelial progenitor cells from peripheral blood. J Mol Cell Cardiol2004; 36: 233–239.
WoywodtABlannADKirschT. Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocol. J Thromb Haemost2006; 4: 671–677.
34.
GallagherKALiuZJXiaoM. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest2007; 117: 1249–1259.
35.
FadiniGPSartoreSSchiavonM. Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia2006; 49: 3075–3084.
36.
FadiniGPSartoreSAgostininC. Significance of endothelial progenitor cells in subjects with diabetes. Diabetes Care2007; 30: 1305–1313.
37.
ChurdchomjanWKheolamaiPManochantrS. Comparison of endothelial progenitor cell function in type 2 diabetes with good and poor glycemic control. BMC Endocr Disord2010; 10: 5–5.
38.
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med1993; 329: 977–986.
39.
UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet1998; 352: 854–865.
40.
ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med2011; 364: 818–828.
41.
WallerstedtESmithUAnderssonCX. Protein kinase C-δ is involved in the inflammatory effect of IL-6 in mouse adipose cells. Diabetologia2010; 53: 946–946.
